drugset / Trial / NCT04346368
Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)
Phase 1/2
Unknown
20 enrolled
Guangzhou Institute of Respiratory Disease
Guangzhou Cellgenes Biotechnology Co.,Ltd · collabGuangzhou Eighth People's Hospital · collabTongji Hospital · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available. For severe cases, it was found that aberrant pathogenic T cells and inflammatory monocytes are rapidly activated and then producing a large number of cytokines and inducing an inflammatory storm.Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate the safety and efficacy of intravenous infusion of mesenchymal stem cells in severe patients with COVID-19.
Timeline
- Start
- 2020-04
- Primary completion
- 2020-12
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BM-MSCs | Cell therapy | 1e+06 cells/kg | Intravenous |